Management of chronic myeloid leukaemia in clinical practice in France: Results of the French subset of patients from the UNIC studyCML management in France

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 307-317

  Michallet, Mauricette ^a   Tulliez, Michel ^b   Corm, Sélim ^c   Gardembas, Martine ^d   Huguet, Francoise ^e   Oukessou, Abderrahim ^f   Bregman, Bruno ^f   Vekhoff, Anne ^g   Ghomari, Kamel ^h   Cambier, Nathalie ⁱ   Guerci Bresler, Agnés ^j  

^a HOSPICES CIVILS DE LYON   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e CHU PURPAN   (France)

^f BRISTOL MYERS SQUIBB   (United States)

^g HÔTEL DIEU   (France)

^h Centre Hospitalier de Beauvais   (France)

ⁱ Groupement Hospitalier de L'Institut Catholique Facultél Libre de Méldecine de Lille   (France)

^j CHU NANCY BRABOIS   (France)

more..

Author keywords

Chronic myeloid leukaemia; Disease management; Drug resistance; Health resources; Imatinib; Toxicity

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CYTOGENETICS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; FRANCE; GENE MUTATION; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RESOURCE ALLOCATION; TREATMENT OUTCOME;

EID: 74549211342     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903479299     Document Type: Article

References (16)

1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293
2. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417
4. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820
5. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009: published online 2 November 2009, doi: 10.1200/JCO. 2009.25.0779
6. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study. Blood 2004;104: Abstract 21
7. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large Phase II trials. Blood 2004;104: Abstract 23
8. Marcucci G, Perrotti D, Caligiuri MA. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed, et al. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 2003;9:1248-1252
9. Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004;18:641-56, ix
10. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111:1039-1043
11. Tardieu S, Brun-Strang C, Berthaud P, et al. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 2005;14:545-553
12. Corm S, Leroyer A, Wemeau M, et al. A retrospective 20-year survey of the incidence of chronic myeloid leukemia in the Northern France region. In: American Society of Hematology, Orlando, FL, USA, 2006
13. Michallet M, Morra E, Steegmann JL, et al. Imatinib resistance and/or intolerance in clinical practice in Europe: The Unmet Needs in CML and Ph\+ALL (UNIC) study. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 1951
14. Morra E, Mauricette M, Steegmann JL, et al. Real-life rates of disease monitoring in clinical practice in Europe: The Unmet Needs in CML and Ph\+ALL (UNIC) study. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 1959
15. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652
16. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363